Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has announced the quotation of 7,335,608 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 1, 2025. This move is part of a previously announced transaction, which may enhance the company’s financial flexibility and market presence, potentially impacting its operations and stakeholder interests positively.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of immuno-oncology therapies. The company is engaged in creating novel cancer treatments that harness the immune system to target and eradicate tumors, positioning itself as a key player in the cancer treatment market.
YTD Price Performance: -77.34%
Average Trading Volume: 1,750,636
Technical Sentiment Signal: Sell
Current Market Cap: A$82.22M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.